From the 1990s to the early 2000s, randomized controlled trials utilizing angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (MRAs) revealed improved outcomes of HF with a reduced ejection fraction (HFrEF). The gene discussed is ACE; the disease is hydrops fetalis.